Market
Olympus agrees $270m BioProtect buyout to expand prostate cancer offerings
Olympus has agreed to acquire BioProtect for $270 million to expand its prostate cancer treatment portfolio. BioProtect's primary product is a tissue-protection spacer system used during radiation therapy for prostate cancer. The acquisition strengthens Olympus's specialty medical and oncology device offerings.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network